JOURNAL OF SHANDONG UNIVERSITY(NATURAL SCIENCE) ›› 2025, Vol. 60 ›› Issue (9): 10-23.doi: 10.6040/j.issn.1671-9352.0.2025.069

Previous Articles    

Chemical composition analysis and the determination of main components of Resina Draconis based on UPLC-QE-Orbitrap-MS

NING Shuyi, DAI Zhaoyuan, FENG Xinchi*   

  1. School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
  • Published:2025-09-10

Abstract: Based on UPLC-QE-Orbitrap-MS, the chemical components of Resina Draconis were identified and the analytical method was established for simultaneous determination of the main components in Resina Draconis. The chromatographic column employed is an ACQUITY UPLC BEH C18(1.7 μm, 2.1×100 mm)column, utilizing a mobile phase of acetonitrile-water containing 0.1% formic acid. A high-energy electrospray ionization source(HESI)used and negative ion mode scanning was applied. By integrating the precise molecular masses of each compound, the fragment information from secondary mass spectrometry, the data reported in the literature, and comparisons with reference substances, the chemical components of Resina Draconis were identified, and a method for the simultaneous determination of the mass fractions of loureirin A, loureirin B, loureirin C, loureirin D, resveratrol, and 7,4'-dihydroxyflavone in Resina Draconis was established based on UPLC-QE-Orbitrap-MS technique. The quantitative analysis method used 0.1% formic acid water(A)and 0.1% formic acid acetonitrile(B)as mobile phase, gradient elution program: 0-2 min, 22%-45%B; 2-6 min, 45%B; 6-7 min, 45%-95%B; 7-8 min, 95%-22%B; 8-11 min, 22%B. Flow rate was set as 0.25 mL/min and column temperature was set as 35 ℃. The inject volume was set as 5 μL. HESI source and parallel reaction monitoring(PRM)scan in negative ion mode was applied, with capillary temperature set as 350 ℃, spray voltage set as 2.8 kV, S-lens level set as 35 kV, sheath gas flow rate set as 35 arb, auxiliary gas flow rate set as 10 arb. The results showed that 25 compounds, 22 flavonoids and 3 stilbenes were identified, 9 of which were compared with the reference standard and identified exactly. Loureirin A, loureirin B, loureirin C, loureirin D, resveratrol, and 7,4'-dihydroxyflavone were determined to be the index components of mass fractions. The linear relationship between the six components was good(r≥0.999 2)in the mass concentration range, and the precision, repeatability and stability met the relevant requirements. The recoveries were 92.2%-105.0%. The method was feasible to determine the mass fractions of 14 batches of Resina Draconis. The mass fractions of loureirin B is 0.41%-7.25%, which is the highest component among the 6 index components. In summary, based on systematic analysis of the chemical components of Resina Draconis, the mass fractions determination methods of 6 main components were established in this study to provide reference for the pharmacodynamic material basis and quality control of Resina Draconis.

Key words: Resina Draconis, UPLC-QE-Orbitrap-MS, quality control, flavonoids, loureirin B

CLC Number: 

  • R284
[1] 杨敏,杨瑞,覃彬华,等. 民族药龙血竭研究进展[J]. 海峡药学,2019,31(11):49-52. YANG Min, YANG Rui, QIN Binhua, et al. Research progress of dragons blood, a national medicine [J]. Strait Pharmaceutical Journal, 2019, 31(11):49-52.
[2] 徐红英,张晓燕. 中药血竭研究进展[J]. 中医药学报,2011,39(4):101-103. XU Hongying, ZHANG Xiaoyan. Research progress of dragons blood[J]. Acta Chinese Medicine and Pharmacology, 2011, 39(4):101-103.
[3] FAN J Y, YI T, SZE-TO C M, et al. A systematic review of the botanical, phytochemical and pharmacological profile of Dracaena cochinchinensis, a plant source of the ethnomedicine “dragons blood” [J]. Molecules, 2014,19(7):10650-10669.
[4] 孙晶,庞道然,郑姣,等. 龙血竭的药理、临床及质量控制研究进展[J]. 中国医院用药评价与分析,2017,17(11):1445-1447. SUN Jing, PANG Daoran, ZHENG Jiao, et al. Research progress in pharmacology, clinic and quality control of dragons blood[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2017, 17(11):1445-1447.
[5] 国家药典委员会. 中华人民共和国药典:一部[M]. 北京:中国医药科技出版社,2020. Chinese Pharmacopoeia Commission. Pharmacopoeia of the Peoples Republic of China: part I [M]. Beijing: China Medical Science and Technology Press, 2020.
[6] 林忆龙,文亦磊,黄洪,等. 龙血竭化学成分及药理作用研究进展[J]. 中国民族民间医药,2020,29(6):50-55. LIN Yilong, WEN Yilei, HUANG Hong, et al. Research progress on chemical constituents and pharmacological effects of dragons blood[J]. Chinese Journal of Ethnomedicine and Ethnopharmacy, 2020, 29(6):50-55.
[7] 王建壮,吕华冲. 比色法测定龙血竭总黄酮含量[J]. 中国实验方剂学杂志,2013,19(16):55-58. WANG Jianzhuang, LV Huachong. content determination of total flavonoids in Resina Draconis by colorimetric method[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2013, 19(16):55-58.
[8] 李竣,朱功俊,陈素,等. HPLC法同时测定不同产地龙血竭中3种黄酮类成分[J]. 中南民族大学学报(自然科学版),2017,36(2):45-48. LI Jun, ZHU Gongjun, CHEN Su, et al. Simultaneous determination of three kinds of flavonoids in Resina Draconis from different regions by HPLC[J]. Journal of South-Central University for Nationalities(Natural Science Edition), 2017, 36(2):45-48.
[9] 李云,萧伟,秦建平,等. HPLC测定龙血竭提取物中龙血素A, B和7,4'-二羟基黄酮的含量[J]. 中国实验方剂学杂志, 2012, 18(3):45-47. LI Yun, XIAO Wei, QIN Jianping, et al. Determination of loureirin A, B and 7,4'-dihydroxy flavone in extract of Resina Draconis by HPLC[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2012, 18(3):45-47.
[10] 张静泽,胡迎庆,郭鹏. 紫外分光光度法测定龙血竭中二氢查耳酮的含量[J]. 中成药,2004,26(6):77-79. ZHANG Jingze, HU Yingqing, GUO Peng. Determination of dihydrochalcone in dragons blood by ultraviolet spectrophotometry[J]. Chinese Traditional Patent Medicine, 2004, 26(6):77-79.
[11] WANG S, LI Y W, ZHANG N X, et al. Screening of ESR2-targeted anti-postmenopausal osteoporosis chemistry from Rehmanniae Radix Preparata based on affinity ultrafiltration with UPLC-QE-Orbitrap-MS[J]. Journal of Chromatography B, 2025, 1251:124419.
[12] ZHANG K Y, LI C N, ZHANG N X, et al. UPLC-QE-orbitrap-based cell metabolomics and network pharmacology to reveal the mechanism of N-benzylhexadecanamide isolated from maca(Lepidium meyenii walp.)against testicular dysfunction[J]. Molecules, 2023, 28(10):4064.
[13] 李涛,谭璐,徐文泱,等. UPLC-Q/Orbitrap MS法检测水产品中12种抗生素残留[J]. 食品工业,2020,41(5):300-303. LI Tao, TAN Lu, XU Wenyang, et al. Determination of 12 kinds of antibiotics in aquatic products by UPLC-Q/orbitrap MS[J]. The Food Industry, 2020, 41(5):300-303.
[14] 汤钜添,陈少茹,张诚光. 基于UPLC-QE-Orbitrap-MS技术鉴定中药三棱入血成分[J]. 深圳中西医结合杂志,2024,34(5):72-74. TANG Jutian, CHEN Shaoru, ZHANG Chengguang. Identification of blood components of rhizoma sparganii based on UPLC-QE-orbitrap-MS technology[J]. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 2024, 34(5):72-74.
[15] 国家药典委员会. 中华人民共和国药典:四部[M]. 北京:中国医药科技出版社,2020. Chinese Pharmacopoeia Commission. Pharmacopoeia of the Peoples Republic of China: part IV[M]. Beijing: China Medical Science and Technology Press, 2020.
[16] JIANG Y, ZHANG G P, YAN D, et al. Bioactivity-guided fractionation of the traditional Chinese medicine Resina Draconis reveals loureirin B as a PAI-1 inhibitor[J]. Evidence-Based Complementary and Alternative Medicine, 2017, 2017:9425963.
[17] BAI X Z, HE T, LIU J Q, et al. Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scarvia TGF-β/Smad pathway[J]. Experimental Dermatology, 2015, 24(5):355-360.
[18] HU J P, ZHANG R, TANG M, et al. Loureirin B inhibits the proliferation of hepatic stellate cells and the Wnt/β-catenin signaling pathway by regulating miR-148-3p[J]. Cellular & Molecular Biology Letters, 2018, 23:35.
[19] LI R, JIA H Y, SI M, et al. Loureirin B protects against cerebral ischemia/reperfusion injury through modulating M1/M2 microglial polarization via STAT6/NF-kappaB signaling pathway[J]. European Journal of Pharmacology, 2023, 953:175860.
[20] FANG H W, DING Y T, XIA S J, et al. Loureirin B promotes insulin secretion through GLP-1R and AKT/PDX1 pathways[J]. European Journal of Pharmacology, 2022, 936:175377.
[21] SHI S J, ZHAO Q R, KE C H, et al. Loureirin B exerts its immunosuppressive effects by inhibiting STIM1/Orai1 and KV1.3 channels[J]. Frontiers in Pharmacology, 2021, 12:685092.
[22] 杨波,郭建恩,韩俊婷,等. 龙血素A对大鼠局灶性脑缺血再灌注引起的脑损伤及机制探讨[J]. 中药新药与临床药理,2010,21(2):103-107. YANG Bo, GUO Jianen, HAN Junting, et al. Effect of loureirin A on focal cerebral ischemia-reperfusion rats and its mechanism[J]. Traditional Chinese Drug Research & Clinical Pharmacology, 2010, 21(2):103-107.
[23] LIU Y S, MI Y, WANG Y P, et al. Loureirin C inhibits ferroptosis after cerebral ischemia reperfusion through regulation of the Nrf2 pathway in mice[J]. Phytomedicine, 2023, 113:154729.
[24] SU X Q, SONG Y L, ZHANG J, et al. Dihydrochalcones and homoisoflavanes from the red resin of Dracaena cochinchinensis(Chinese dragonsblood)[J]. Fitoterapia, 2014, 99:64-71.
[25] CHENG L, JIN Z X, ZHAO R, et al. Resveratrol attenuates inflammation and oxidative stress induced by myocardial ischemia-reperfusion injury: role of Nrf2/ARE pathway[J]. International Journal of Clinical and Experimental Medicine, 2015, 8(7):10420-10428.
[26] JIANG M, SU X, LIU J L, et al. Systems pharmacology-dissection of the molecular mechanisms of dragons blood in improving ischemic stroke prognosis[J]. Evidence-Based Complementary and Alternative Medicine, 2020, 2020:4858201.
[27] 朱智德,吴玉强. 剑叶龙血树繁育种植技术与人工诱导机制研究综述[J]. 大众科技,2015,17(12):99-101. ZHU Zhide, WU Yuqiang. The research summarizes of D.cochinchinensis about breeding cultivation technology and artificial induction mechanism[J]. Popular Science & Technology, 2015, 17(12):99-101.
[1] Liang GUI,Yao XU,Shizhu HE,Yuanzhe ZHANG,Kang LIU,Jun ZHAO. Factual error detection in knowledge graphs based on dynamic neighbor selection [J]. JOURNAL OF SHANDONG UNIVERSITY(NATURAL SCIENCE), 2024, 59(7): 76-84.
[2] . Study on the determination method of total flavonoids in ginkgo biloba extract [J]. J4, 2009, 44(5): 40-44.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!